Image For Activity Cover
Stigma, Drugs, and Policy: How Language Drives Change
John Kelly, PhD, ABPP, Professor of Psychiatry in Addiction Medicine at Harvard Medical School, Founder and Director of the Recovery Research Institute (RRI) at Massachusetts General Hospital (MGH), Associate Director of the Center for Addiction Medicine (CAM) at MGH, Program Director of the Addiction Recovery Management Service (ARMS)
Target Audience
This activity is primarily designed to meet the needs of primary care physicians, specialty care physicians, and allied professional staff.
Webinar Description
Language matters when it comes to treating substance use disorders (SUD). Stigma has been proven to have a negative impact on health outcomes, not only leading many individuals with SUD to not seek treatment, but also influencing how health professionals treat their patients. Using non-stigmatizing, person-centered, and recovery-oriented language can help providers facilitate engagement in treatment for individuals with SUD. This webinar will explore the ever-evolving landscape of language around SUD and discuss strategies for healthcare providers and allied health professionals to address stigma within your practice.
Educational Objectives

At the conclusion of this activity, learners should be able to:

  • Discuss the importance of language in treating substance use disorders (SUD).
  • Review the history and context of changing language around SUD.
  • Examine the evidence demonstrating the impact of stigmatizing language on the provision, quality and allocation of resources for SUD care.
  • Identify strategies for addressing stigma in policy and practice settings.
Availability: On-Demand
Expires on 07/23/2023
Cost: FREE
Credit Offered:
1 Attendance Credit
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.

Funding for this initiative was made possible (in part) by grant nos. 6H79TI081968 and 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For Buprenorphine Training Inquiries, email PCSS.


Powered By